The authors demonstrated increased binding of a specific GA binding protein B1L (GABPB1L)-isoform–containing complex to the mutant telomerase reverse transcriptase (TERT) promoter. They found that TERT promoter mutant glioblastoma cells, unlike wild-type cells, exhibited a critical near-term dependence on GABPB1L for proliferation.
[Proceedings of the National Academy of Sciences of the United States of America]
6807162
{6807162:59SCYP6D}
apa
50
1
160431
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-5fe5503055dbf0422311eb73fefc7c07%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%2259SCYP6D%22%2C%22library%22%3A%7B%22id%22%3A6807162%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Amen%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAmen%2C%20A.%20M.%2C%20Fellmann%2C%20C.%2C%20Soczek%2C%20K.%20M.%2C%20Ren%2C%20S.%20M.%2C%20Lew%2C%20R.%20J.%2C%20Knott%2C%20G.%20J.%2C%20Park%2C%20J.%20E.%2C%20McKinney%2C%20A.%20M.%2C%20Mancini%2C%20A.%2C%20Doudna%2C%20J.%20A.%2C%20%26amp%3B%20Costello%2C%20J.%20F.%20%282021%29.%20Cancer-specific%20loss%20of%20TERT%20activation%20sensitizes%20glioblastoma%20to%20DNA%20damage.%20%3Ci%3EProceedings%20of%20the%20National%20Academy%20of%20Sciences%3C%5C%2Fi%3E%2C%20%3Ci%3E118%3C%5C%2Fi%3E%2813%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.2008772118%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.2008772118%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6807162%26amp%3Bitem_key%3D59SCYP6D%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cancer-specific%20loss%20of%20TERT%20activation%20sensitizes%20glioblastoma%20to%20DNA%20damage%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20M.%22%2C%22lastName%22%3A%22Amen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christof%22%2C%22lastName%22%3A%22Fellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katarzyna%20M.%22%2C%22lastName%22%3A%22Soczek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shawn%20M.%22%2C%22lastName%22%3A%22Ren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20J.%22%2C%22lastName%22%3A%22Lew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gavin%20J.%22%2C%22lastName%22%3A%22Knott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesslyn%20E.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20M.%22%2C%22lastName%22%3A%22McKinney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Mancini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20A.%22%2C%22lastName%22%3A%22Doudna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20F.%22%2C%22lastName%22%3A%22Costello%22%7D%5D%2C%22abstractNote%22%3A%22Most%20glioblastomas%20%28GBMs%29%20achieve%20cellular%20immortality%20by%20acquiring%20a%20mutation%20in%20the%20telomerase%20reverse%20transcriptase%20%28TERT%29%20promoter.%20TERT%20promoter%20mutations%20create%20a%20binding%20site%20for%20a%20GA%20binding%20protein%20%28GABP%29%20transcription%20factor%20complex%2C%20whose%20assembly%20at%20the%20promoter%20is%20associated%20with%20TERT%20reactivation%20and%20telomere%20maintenance.%20Here%2C%20we%20demonstrate%20increased%20binding%20of%20a%20specific%20GABPB1L-isoform%5Cu2013containing%20complex%20to%20the%20mutant%20TERT%20promoter.%20Furthermore%2C%20we%20find%20that%20TERT%20promoter%20mutant%20GBM%20cells%2C%20unlike%20wild-type%20cells%2C%20exhibit%20a%20critical%20near-term%20dependence%20on%20GABPB1L%20for%20proliferation%2C%20notably%20also%20posttumor%20establishment%20in%20vivo.%20Up-regulation%20of%20the%20protein%20paralogue%20GABPB2%2C%20which%20is%20normally%20expressed%20at%20very%20low%20levels%2C%20can%20rescue%20this%20dependence.%20More%20importantly%2C%20when%20combined%20with%20frontline%20temozolomide%20%28TMZ%29%20chemotherapy%2C%20inducible%20GABPB1L%20knockdown%20and%20the%20associated%20TERT%20reduction%20led%20to%20an%20impaired%20DNA%20damage%20response%20that%20resulted%20in%20profoundly%20reduced%20growth%20of%20intracranial%20GBM%20tumors.%20Together%2C%20these%20findings%20provide%20insights%20into%20the%20mechanism%20of%20cancer-specific%20TERT%20regulation%2C%20uncover%20rapid%20effects%20of%20GABPB1L-mediated%20TERT%20suppression%20in%20GBM%20maintenance%2C%20and%20establish%20GABPB1L%20inhibition%20in%20combination%20with%20chemotherapy%20as%20a%20therapeutic%20strategy%20for%20TERT%20promoter%20mutant%20GBM.%5CnAuthor%20Information%5CnAlexandra%20M.%20Amena%2Cb%2C1%2C%20Christof%20Fellmanna%2Cc%2Cd%2C1%2C%20Katarzyna%20M.%20Soczeka%2C%20Shawn%20M.%20Rena%2C%20Rachel%20J.%20Lewc%2C%20Gavin%20J.%20Knotta%2C%20Jesslyn%20E.%20Parka%2C%20Andrew%20M.%20McKinneyb%2C%20Andrew%20Mancinib%2C%20Jennifer%20A.%20Doudnaa%2Cc%2Ce%2Cf%2Cg%2Ch%2C2%2C%20and%20Joseph%20F.%20Costellob%2C2aDepartment%20of%20Molecular%20and%20Cell%20Biology%2C%20University%20of%20California%2C%20Berkeley%2C%20CA%2094720%3BbDepartment%20of%20Neurological%20Surgery%2C%20University%20of%20California%2C%20San%20Francisco%2C%20CA%2094158%3BcGladstone%20Institute%20of%20Data%20Science%20and%20Biotechnology%2C%20Gladstone%20Institutes%2C%20San%20Francisco%2C%20CA%2094158%3BdDepartment%20of%20Cellular%20and%20Molecular%20Pharmacology%2C%20University%20of%20California%2C%20San%20Francisco%2C%20CA%2094158%3BeDepartment%20of%20Chemistry%2C%20University%20of%20California%2C%20Berkeley%2C%20CA%2094720%3BfMolecular%20Biophysics%20and%20Integrated%20Bioimaging%20Division%2C%20Lawrence%20Berkeley%20National%20Laboratory%2C%20Berkeley%2C%20CA%2094720%3BgHHMI%2C%20University%20of%20California%2C%20Berkeley%2C%20CA%2094720%3BhInnovative%20Genomics%20Institute%2C%20University%20of%20California%2C%20Berkeley%2C%20CA%2094720Edited%20by%20James%20E.%20Cleaver%2C%20University%20of%20California%2C%20San%20Francisco%20Medical%20Center%2C%20San%20Francisco%2C%20CA%2C%20and%20approved%20February%2023%2C%202021%20%28received%20for%20review%20May%204%2C%202020%29%5CnFootnotes%5Cu21b51A.M.A.%20and%20C.F.%20contributed%20equally%20to%20this%20work.%5Cu21b52To%20whom%20correspondence%20may%20be%20addressed.%20Email%3A%20doudna%40berkeley.edu%20or%20joseph.costello%40ucsf.edu.Author%20contributions%3A%20A.M.A.%2C%20C.F.%2C%20J.A.D.%2C%20and%20J.F.C.%20conceived%20the%20project%3B%20A.M.A.%20and%20C.F.%20designed%2C%20planned%2C%20and%20carried%20out%20experiments%2C%20and%20analyzed%20and%20interpreted%20data%3B%20K.M.S.%2C%20G.J.K.%2C%20and%20J.E.P.%20conceived%2C%20designed%2C%20and%20carried%20out%20protein%20purification%20and%20DNA%20binding%20assays%3B%20S.M.R.%20and%20R.J.L.%20helped%20plan%20and%20carry%20out%20experiments%3B%20A.M.M.%20and%20A.M.%20helped%20plan%20experiments%20and%20interpret%20data%3B%20J.A.D.%20and%20J.F.C.%20supervised%20all%20experiments%3B%20and%20A.M.A.%2C%20C.F.%2C%20J.A.D.%2C%20and%20J.F.C.%20wrote%20the%20manuscript%20with%20input%20from%20all%20authors.Competing%20interest%20statement%3A%20The%20Regents%20of%20the%20University%20of%20California%20have%20patents%20issued%20and%20pending%20for%20CRISPR%20technologies%20on%20which%20J.A.D.%20is%20an%20inventor.%20C.F.%20is%20a%20co-founder%20of%20Mirimus%2C%20Inc.%20J.A.D.%20is%20a%20co-founder%20of%20Caribou%20Biosciences%2C%20Editas%20Medicine%2C%20Intellia%20Therapeutics%2C%20Scribe%20Therapeutics%2C%20and%20Mammoth%20Biosciences.%20J.A.D.%20is%20a%20scientific%20advisory%20board%20member%20of%20Caribou%20Biosciences%2C%20Intellia%20Therapeutics%2C%20eFFECTOR%20Therapeutics%2C%20Scribe%20Therapeutics%2C%20Synthego%2C%20Metagenomi%2C%20Mammoth%20Biosciences%2C%20and%20Inari.%20J.A.D.%20is%20a%20Director%20at%20Johnson%20%26%20Johnson%20and%20has%20sponsored%20research%20projects%20by%20Pfizer%2C%20Roche%20Biopharma%2C%20and%20Biogen.%20J.F.C.%20is%20a%20co-founder%20of%20Telo%20Therapeutics%2C%20Inc.%20and%20has%20ownership%20interests.%20The%20other%20authors%20declare%20no%20competing%20interests.This%20article%20is%20a%20PNAS%20Direct%20Submission.This%20article%20contains%20supporting%20information%20online%20at%20https%3A%5C%2F%5C%2Fwww.pnas.org%5C%2Flookup%5C%2Fsuppl%5C%2Fdoi%3A10.1073%5C%2Fpnas.2008772118%5C%2F-%5C%2FDCSupplemental.%22%2C%22date%22%3A%222021%5C%2F03%5C%2F30%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1073%5C%2Fpnas.2008772118%22%2C%22ISSN%22%3A%220027-8424%2C%201091-6490%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.pnas.org%5C%2Fcontent%5C%2F118%5C%2F13%5C%2Fe2008772118%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-03-23T21%3A12%3A14Z%22%7D%7D%5D%7D
Amen, A. M., Fellmann, C., Soczek, K. M., Ren, S. M., Lew, R. J., Knott, G. J., Park, J. E., McKinney, A. M., Mancini, A., Doudna, J. A., & Costello, J. F. (2021). Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. Proceedings of the National Academy of Sciences, 118(13). https://doi.org/10.1073/pnas.2008772118 Cite
